Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Down 2.1%

Adaptimmune Therapeutics plc (NASDAQ:ADAP) shares dropped 2.1% during mid-day trading on Tuesday . The stock traded as low as $1.41 and last traded at $1.41. Approximately 62,343 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 1,897,795 shares. The stock had previously closed at $1.44.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of Adaptimmune Therapeutics in a report on Friday, December 29th. They issued a “hold” rating on the stock.

Adaptimmune Therapeutics Stock Up 3.9 %

The business has a fifty day moving average of $1.28 and a 200 day moving average of $0.86. The company has a market cap of $1.57 billion, a P/E ratio of -2.87 and a beta of 2.40.

Hedge Funds Weigh In On Adaptimmune Therapeutics

A number of institutional investors have recently bought and sold shares of ADAP. Two Sigma Investments LP purchased a new position in shares of Adaptimmune Therapeutics in the fourth quarter worth $33,000. UBS Group AG raised its position in Adaptimmune Therapeutics by 1,090.8% in the 4th quarter. UBS Group AG now owns 23,625 shares of the biotechnology company’s stock worth $34,000 after buying an additional 21,641 shares during the last quarter. Virtu Financial LLC bought a new position in Adaptimmune Therapeutics during the 1st quarter valued at about $50,000. X Square Capital LLC bought a new position in Adaptimmune Therapeutics during the 2nd quarter valued at about $25,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Adaptimmune Therapeutics during the 4th quarter valued at about $48,000. 31.37% of the stock is owned by institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.